1031 related articles for article (PubMed ID: 34755538)
21. Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.
Rein T
J Cell Biochem; 2022 Feb; 123(2):155-160. PubMed ID: 34668225
[TBL] [Abstract][Full Text] [Related]
22. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
[TBL] [Abstract][Full Text] [Related]
23. Drug repurposing strategies and key challenges for COVID-19 management.
Mule S; Singh A; Greish K; Sahebkar A; Kesharwani P; Shukla R
J Drug Target; 2022 Apr; 30(4):413-429. PubMed ID: 34854327
[TBL] [Abstract][Full Text] [Related]
24. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.
Jan JT; Cheng TR; Juang YP; Ma HH; Wu YT; Yang WB; Cheng CW; Chen X; Chou TH; Shie JJ; Cheng WC; Chein RJ; Mao SS; Liang PH; Ma C; Hung SC; Wong CH
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33452205
[TBL] [Abstract][Full Text] [Related]
25. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
More SA; Patil AS; Sakle NS; Mokale SN
Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
[TBL] [Abstract][Full Text] [Related]
26. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
27.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
28. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
Altulea D; Maassen S; Baranov MV; van den Bogaart G
J Mol Cell Biol; 2021 Jul; 13(3):175-184. PubMed ID: 33693723
[TBL] [Abstract][Full Text] [Related]
29. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
30. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
32. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
33. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
34. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
35. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
Ni Y; Liao J; Qian Z; Wu C; Zhang X; Zhang J; Xie Y; Jiang S
Bioorg Med Chem; 2022 Jan; 53():116523. PubMed ID: 34875467
[TBL] [Abstract][Full Text] [Related]
37. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
38. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
39. Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target.
Li C; Chu H; Liu X; Chiu MC; Zhao X; Wang D; Wei Y; Hou Y; Shuai H; Cai J; Chan JF; Zhou J; Yuen KY
Emerg Microbes Infect; 2020 Dec; 9(1):2663-2672. PubMed ID: 33179566
[TBL] [Abstract][Full Text] [Related]
40. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.
Dyall J; Coleman CM; Hart BJ; Venkataraman T; Holbrook MR; Kindrachuk J; Johnson RF; Olinger GG; Jahrling PB; Laidlaw M; Johansen LM; Lear-Rooney CM; Glass PJ; Hensley LE; Frieman MB
Antimicrob Agents Chemother; 2014 Aug; 58(8):4885-93. PubMed ID: 24841273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]